Physician profile
Robert A Shultz
NPI 1396734943
$5,390.93
in general payments reported to CMS, 2019-2025
28 companies · $1,575 in 2025
The $1,575 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $162 · 2021: $186 · 2022: $598 · 2023: $1,026 · 2024: $1,340 · 2025: $1,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,892 · Education: $50.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,891.50 |
| Education | $50.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,972.40 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $618.01 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $355.07 | 2022-2025 | Dupixent |
| Novo Nordisk INC | $265.73 | 2025 | Wegovy |
| Genzyme Corporation | $239.66 | 2022-2025 | |
| Madrigal Pharmaceuticals | $237.28 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $235.51 | 2023-2024 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $233.61 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $164.44 | 2024-2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $145.21 | 2021-2025 | Entyvio, Eohilia |
| Enterra Medical, INC. | $121.55 | 2025 | |
| Medical Device Business Services, INC. | $116.50 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.94 | 2019 | |
| Janssen Scientific Affairs, LLC | $95.99 | 2024 | |
| Boston Scientific Corporation | $71.65 | 2024 | Exalt Model D |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $63.82 | 2022-2024 | Dificid |
| Celltrion USA INC. | $53.68 | 2023-2025 | Yuflyma, Zymfentra, Vegzelma |
| Amgen INC. | $50.54 | 2023 | Amjevita, Avsola |
| Celgene Corporation | $49.28 | 2023-2024 | Zeposia |
| Lilly USA, LLC | $47.66 | 2024-2025 | Omvoh |
| Allergan, INC. | $27.90 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $26.45 | 2023 | Ocaliva |
| Fresenius Kabi USA, LLC | $21.21 | 2023 | Idacio |
| Braintree Laboratories, INC. | $17.54 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.15 | 2023 | Givlaari |
| Ferring Pharmaceuticals INC. | $16.40 | 2024 | Rebyota |
| Evoke Pharma, INC. | $16.27 | 2022 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Shultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.